Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780751 | 0.85 | CA2 (0.45) | CA2LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL4850001 | 0.85 | CA2 (0.33) | CA2LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL1965147 | 0.82 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL874656 | 0.78 | ALDH1A1 (0.52) | CA2LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL671168 | 0.77 | — | — | |
| SCHEMBL7920276 | 0.75 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL571847 | 0.74 | TRPA1 (0.50) | CA2LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL9097641 | 0.74 | IDO1 (0.46) | CA2LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL2183097 | 0.74 | G6PD (0.47) | CA2LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL7156428 | 0.74 | CES2 (0.39) | CA2LMNAHPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776382-B1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2018-09-19 | — | — | EP | claimed |
| EP-3131897-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-06-15 | — | — | EP | disclosed |
| US-10973936-B2 | 18F-saccharide-folates | Merck & Cie (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20190255200-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10322195-B2 | 18F-saccharide-folates | Merck & Cie (CH) | 2019-06-18 | — | — | US | disclosed |
| EP-3131896-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2776382-B1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-9969724-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9808445-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170129880-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME LLC | 2017-05-11 | — | — | US | disclosed |
| EP-0150202-B1 | DI/TETRA-HYDROQUINOLINES | BEECHAM GROUP PLC (GB) | 1988-07-06 | — | — | EP | disclosed |
| EP-0218373-A2 | Chroman derivatives and analogues having antihypertensive activity | BEECHAM GROUP PLC (GB) | 1987-04-15 | — | — | EP | disclosed |
| EP-0214743-A2 | Use of quinoline derivatives in the manufacture of medicaments for the treatment of cerebrovascular disorders and cerebral senility | BEECHAM GROUP PLC (GB) | 1987-03-18 | — | — | EP | disclosed |
| US-4626524-A | Antiviral peptides | THE GENERAL HOSPITAL CORPORATION (US) | 1986-12-02 | — | — | US | disclosed |
| EP-0191854-A1 | ANTIVIRAL PEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 1986-08-27 | — | — | EP | disclosed |
| WO-1986001408-A1 | ANTIVIRAL PEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 1986-03-13 | — | — | WO | disclosed |
| EP-0150202-A1 | DI/TETRA-HYDROQUINOLINES. | BEECHAM GROUP PLC (GB) | 1985-08-07 | — | — | EP | disclosed |
| WO-1985000602-A1 | DI/TETRA-HYDROQUINOLINES | BEECHAM GROUP P.L.C. (GB) | 1985-02-14 | — | — | WO | disclosed |
| US-4411899-A | Substituted derivatives of amino alkane diols as gastric secretion inhibitors | MERCK & CO., INC. (US) | 1983-10-25 | — | — | US | disclosed |
| US-3962226-A | 3-NITROOXYCEPHAM COMPOUNDS AND PROCESS FOR PREPARING DESACETOXYCEPHALOSPORINS THEREFROM | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129880-A1 | FACTOR IXa INHIBITORS | F9, F12, TFPI | CA2 908/4885LMNA 89/4885HPGD 1717/4885 |
| US-10322195-B2 | 18F-saccharide-folates | FOLR1, FOLR2, FOLH1 | CA2 3602/4885LMNA 4857/4885HPGD 532/4885 |
| US-10973936-B2 | 18F-saccharide-folates | FOLR1, FOLR2, FOLH1 | CA2 3502/4885LMNA 4865/4885HPGD 418/4885 |
| US-20190255200-A1 | 18F-SACCHARIDE-FOLATES | FOLR1, FOLR2, FOLH1 | CA2 3502/4885LMNA 4865/4885HPGD 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.